The Washington Post report, citing an unnamed official familiar with the plan, said the U.S. government is launching COVID-19 vaccine boosters for certain high-risk groups: people over the age of 65 and those with compromised immune systems. We plan to approve another round of dosing soon.
The spring booster plan for at-risk individuals in the US is similar to the booster offers already in place in Canada and the UK, and the country largely agrees with updated recommendations released last week by the World Health Organization. The Agency’s Advisory Group on Immunization states that, at this time, healthy adults and children do not need additional boosters in the short term, but certain high-risk groups should be offered boosters every 6 to 12 months. I decided that I needed to.
The US Spring Booster will be offered to high-risk people who have been at least four months since their last injection and need additional protection, The Washington Post reports. The US last approved a booster dose in September. This means that some of the high-risk groups may have been around 7 months since their last dose.
The Food and Drug Administration will be the first to announce approval before the dosage is available. This is reportedly to be done in the next few weeks. This is expected to happen soon and doses will be available soon. The federal government has tons of boosters, so they’ll probably be given away for free to everyone who wants them.
The approval is for another shot of the bivalent booster that targets both the ancestral coronavirus strain and the more recent Omicron subvariants BA.4 and BA.5. Omicron subvariants continue to dominate infections in the United States and globally. Omicron subvariant XBB.1.5 now accounts for an estimated 88% of cases in the United States, according to the CDC. XBB.1.5 is his XBB strain resulting from recombination of two BA.2 substrains.
Real-world data and clinical studies show that bivalent boosters generally hold up well against the Omicron subvariety in terms of long-term protection from severe disease and short-term protection from infection. However, some research suggests that older people and those with weakened immune systems may need to take it more often to provide better protection against serious illness. .
Dosage Controversy
Still, experts express differing opinions about who, when, and with what should be boosted. However, opinions are divided on vaccination for the elderly, with some suggesting an age limit from the 50s to the 70s, and some saying that it should depend heavily not only on age but also on health status.
Although age and immune status are high-risk factors identified for the Spring Booster in the United States, WHO advisors suggest that high-risk definitions include pregnant women, young people with significant comorbidities (such as heart disease and diabetes). was more comprehensive, including In addition to frontline health care workers, the elderly and immunocompromised people.
A study published last month in Nature found that giving boosters during pregnancy, especially in the third trimester, reduced the risk of newborns being hospitalized with COVID-19 in the first four months of life. It is unclear whether the FDA will include updated approvals for pregnant women in its expected spring booster announcement, or whether the FDA will make provisions for other high-risk groups identified by WHO advisors. is.
So far, the FDA has consistently touted plans to treat booster doses of COVID-19 like seasonal flu shots, with represcription decisions each spring and renewed prophylaxis each fall. Inoculation is widely deployed. Whether the agency will limit boosters to select groups, as the WHO advises for now, could be a topic of major debate among the FDA’s advisory group.
Future booster formulas are also likely to be controversial, with some experts suggesting that monovalent boosters targeting only the current Omicron strain would be better than bivalent formulas.
So far, only 16.5% of the US population and only 42% of people over the age of 65 are on bivalent booster doses.
